


CLAIMS

1. A compound of formula (I),



(I)

its stereoisomers and mixtures thereof, its polymorphs and mixtures thereof, and the pharmaceutically acceptable solvates and addition salts of all of them, wherein the central benzene ring may be substituted in *meta*- or *para*-position and,

-A is a radical selected from the group consisting of -OR₁, -NR₂OR₁ and -NR₂R₃; wherein R₁, R₂ and R₃ independently represent -H or -(C₁-C₄)-alkyl;

-W- is a biradical selected from the group: -NH-CH(E)-, -N(E)-CH₂- and -N(D)-CH₂-CH₂-; wherein E is a radical of the -G-I-J-K type and D is a radical of the -G-I'-J-K type where:

-G- is a bond or a -(CH₂)₁₋₄- biradical;

-I- is a biradical of a cycle selected from the following groups:

a) cyclopropane, cyclobutane, cyclopentane, cyclohexane and cyclohexene, all optionally substituted by one or several radicals independently selected from -OH, oxo (=O), -CHO, -SH, -NO₂, -CN, -F, -Cl, -Br,

(C₁-C₄) - alkanoyl, (C₁-C₄) - alkoxy carbonyl,
(C₁-C₄) - alkanoyloxy, (C₁-C₄) - alkylsulphanyl,
(C₁-C₄) - alkylsulphenyl, (C₁-C₄) - alkylsulphonyl,
(C₁-C₄) - alkyloxy-SO₂-, (C₁-C₄) - alkyl-SO₂O-,
-NR₂R₃, -CONR₂R₃, (C₁-C₄) - alkyl optionally
substituted by one or several -OH or -F, and
(C₁-C₄) - alkoxyl optionally substituted by one
or several -OH or -F;

b) a five- or six-membered aromatic heterocycle
containing from one to three heteroatoms
selected from O, S and N, this heterocycle
being optionally substituted by one or several
radicals independently selected from -OH, oxo
(=O), -CHO, -SH, -NO₂, -CN, -F, -Cl, -Br,
(C₁-C₄) - alkanoyl, (C₁-C₄) - alkoxy carbonyl,
(C₁-C₄) - alkanoyloxy, (C₁-C₄) - alkylsulphanyl,
(C₁-C₄) - alkylsulphenyl, (C₁-C₄) - alkylsulphonyl,
(C₁-C₄) - alkyloxy-SO₂-, (C₁-C₄) - alkyl-SO₂O-,
-NR₂R₃, -CONR₂R₃, (C₁-C₄) - alkyl optionally
substituted by one or several -OH or -F, and
(C₁-C₄) - alkoxyl optionally substituted by one
or several -OH or -F;

c) benzene or benzene substituted by one or
several radicals independently selected from
-OH, -CHO, -SH, -NO₂, -CN, -F, -Cl, -Br,
(C₁-C₄) - alkanoyl, (C₁-C₄) - alkoxy carbonyl,
(C₁-C₄) - alkanoyloxy, (C₁-C₄) - alkylsulphanyl,
(C₁-C₄) - alkylsulphenyl, (C₁-C₄) - alkylsulphonyl,
(C₁-C₄) - alkyloxy-SO₂-, (C₁-C₄) - alkyl-SO₂O-,
-NR₂R₃, -CONR₂R₃, (C₁-C₄) - alkyl optionally
substituted by one or several -OH or -F, and
(C₁-C₄) - alkoxyl optionally substituted by one
or several -OH or -F; and

d) a bicyclic system consisting of a benzene fused with a five- or six-membered ring optionally containing from one to three heteroatoms selected from O, S and N, this bicyclic system being optionally substituted by one or several radicals independently selected from -OH, oxo (=O), -CHO, -SH, -NO₂, -CN, -F, -Cl, -Br, (C₁-C₄)-alkanoyl, (C₁-C₄)-alkoxycarbonyl, (C₁-C₄)-alkanoyloxy, (C₁-C₄)-alkylsulphanyl, (C₁-C₄)-alkylsulphenyl, (C₁-C₄)-alkylsulphonyl, (C₁-C₄)-alkyloxy-SO₂-, (C₁-C₄)-alkyl-SO₂O-, -NR₂R₃, -CONR₂R₃, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F;

-J- is a bond or a biradical selected from the following groups:

- a) -(CH₂)₁₋₄-alkylidene;
- b) -O-, -S-, -SO-, -SO₂-, -CO-, -OCO-, -COO-, -OCONR₂-, -NR₂COO-, -CONR₂-, -NR₂CO-, -NR₂-, -NR₂SO₂-, -SO₂NR₂-, and
- c) -O-(C₁-C₄)-, -(C₁-C₄)-O-, -S-(C₁-C₄)-, -(C₁-C₄)-S-, -SO-(C₁-C₄)-, -(C₁-C₄)-SO-, -SO₂-(C₁-C₄)-, -(C₁-C₄)-SO₂-, -OCO-(C₁-C₄)-, -(C₁-C₄)-OCO-, -(C₁-C₄)-COO-, -OCONR₂-(C₁-C₄)-, -NR₂COO-(C₁-C₄)-, -(C₁-C₄)-OCONR₂-, -(C₁-C₄)-NR₂COO-, -CONR₂-(C₁-C₄)-, -NR₂CO-(C₁-C₄)-, -(C₁-C₄)-CONR₂-, -(C₁-C₄)-NR₂CO-, -NR₂-(C₁-C₄)-, -(C₁-C₄)-NR₂-, -SO₂NR₂-(C₁-C₄)-, -(C₁-C₄)-SO₂NR₂-, -(C₁-C₄)-NR₂SO₂-;

-K is a radical selected from the following groups:

- a) -H;
- b) (C₁-C₄)-alkyl;
- c) a radical from a cycle selected from the following: cyclopropane, cyclobutane, cyclopentane, cyclohexane and cyclohexene, all of them optionally substituted by one or several radicals independently selected from -OH, oxo (=O), -CHO, -SH, -NO₂, -CN, -F, -Cl, -Br, (C₁-C₄)-alkanoyl, (C₁-C₄)-alkoxycarbonyl, (C₁-C₄)-alkanoyloxy, (C₁-C₄)-alkylsulphanyl, (C₁-C₄)-alkylsulphenyl, (C₁-C₄)-alkylsulphonyl, (C₁-C₄)-alkyloxy-SO₂-, (C₁-C₄)-alkyl-SO₂O-, -NR₂R₃, -CONR₂R₃, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F;
- d) a radical from a five- or six-membered heterocycle containing from one to three heteroatoms selected from O, S and N, being this heterocycle optionally substituted by one or several radicals independently selected from -OH, oxo (=O), -CHO, -SH, -NO₂, -CN, -F, -Cl, -Br, (C₁-C₄)-alkanoyl, (C₁-C₄)-alkoxycarbonyl, (C₁-C₄)-alkanoyloxy, (C₁-C₄)-alkylsulphanyl, (C₁-C₄)-alkylsulphenyl, (C₁-C₄)-alkylsulphonyl, (C₁-C₄)-alkyloxy-SO₂-, (C₁-C₄)-alkyl-SO₂O-, -NR₂R₃, -CONR₂R₃, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F; and
- e) phenyl or phenyl optionally substituted by one or several radicals independently selected from -OH, -CHO, -SH, -NO₂, -CN, -F, -Cl, -Br,

(C₁-C₄) - alkanoyl, (C₁-C₄) - alkoxy carbonyl,
(C₁-C₄) - alkanoyloxy, (C₁-C₄) - alkylsulphinyloxy,
(C₁-C₄) - alkylsulphenyl, (C₁-C₄) - alkylsulphonyl,
(C₁-C₄) - alkyloxy-SO₂-, (C₁-C₄) - alkyl-SO₂O-,
-NR₂R₃, -CONR₂R₃, (C₁-C₄) - alkyl optionally
substituted by one or several -OH or -F, and
(C₁-C₄) - alkoxyloxy optionally substituted by one
or several -OH or -F;

-I' - is a biradical of a cycle selected from the
following groups:

a) cyclopropane, cyclobutane, cyclopentane,
cyclohexane and cyclohexene, all optionally
substituted by one or several radicals
independently selected from -OH, oxo (=O),
-CHO, -SH, -NO₂, -CN, -F, -Cl, -Br,
(C₁-C₄) - alkanoyl, (C₁-C₄) - alkoxy carbonyl,
(C₁-C₄) - alkanoyloxy, (C₁-C₄) - alkylsulphinyloxy,
(C₁-C₄) - alkylsulphenyl, (C₁-C₄) - alkylsulphonyl,
(C₁-C₄) - alkyloxy-SO₂-, (C₁-C₄) - alkyl-SO₂O-,
-NR₂R₃, -CONR₂R₃, (C₁-C₄) - alkyl optionally
substituted by one or several -OH or -F, and
(C₁-C₄) - alkoxyloxy optionally substituted by one
or several -OH or -F;

b) a five- or six-membered aromatic heterocycle
containing from one to three heteroatoms
selected from O, S and N, being this
heterocycle optionally substituted by one or
several radicals independently selected from
-OH, oxo (=O), -CHO, -SH, -NO₂, -CN, -F, -Cl,
-Br, (C₁-C₄) - alkanoyl, (C₁-C₄) - alkoxy carbonyl,
(C₁-C₄) - alkanoyloxy, (C₁-C₄) - alkylsulphinyloxy,
(C₁-C₄) - alkylsulphenyl, (C₁-C₄) - alkylsulphonyl,
(C₁-C₄) - alkyloxy-SO₂-, (C₁-C₄) - alkyl-SO₂O-,

-NR₂R₃, -CONR₂R₃, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F;

- c) benzene substituted by one or several radicals independently selected from -OH, -CHO, -SH, -NO₂, -CN, -F, -Cl, -Br, (C₁-C₄)-alkanoyl, (C₁-C₄)-alkoxycarbonyl, (C₁-C₄)-alkanoyloxy, (C₁-C₄)-alkylsulphanyl, (C₁-C₄)-alkylsulphenyl, (C₁-C₄)-alkylsulphonyl, (C₁-C₄)-alkyloxy-SO₂-, (C₁-C₄)-alkyl-SO₂O-, -NR₂R₃, -CONR₂R₃, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F; and
- d) a bicyclic system consisting of a benzene fused with a five- or six-membered ring optionally containing from one to three heteroatoms selected from O, S and N, being this bicyclic system optionally substituted by one or several radicals independently selected from -OH, oxo (=O), -CHO, -SH, -NO₂, -CN, -F, -Cl, -Br, (C₁-C₄)-alkanoyl, (C₁-C₄)-alkoxycarbonyl, (C₁-C₄)-alkanoyloxy, (C₁-C₄)-alkylsulphanyl, (C₁-C₄)-alkylsulphenyl, (C₁-C₄)-alkylsulphonyl, (C₁-C₄)-alkyloxy-SO₂-, (C₁-C₄)-alkyl-SO₂O-, -NR₂R₃, -CONR₂R₃, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F;

-Z is a radical selected from the following groups:

- a) -Q-I-J-T wherein

-Q- is a biradical $-(CH_2)_{1-3}-$;
-I- is as defined above;
-J- is as defined above; and
-T is a radical selected from the following groups:

- a.a) -H;
- a.b) (C_1-C_4) -alkyl;
- a.c) a radical from a cycle selected from the following: cyclopropane, cyclobutane, cyclopentane, cyclohexane and cyclohexene, all of them optionally substituted by one or several radicals independently selected from -OH, oxo (=O), -CHO, -SH, -NO₂, -CN, -F, -Cl, -Br, (C_1-C_4) -alkanoyl, (C_1-C_4) -alkoxycarbonyl, (C_1-C_4) -alkanoyloxy, (C_1-C_4) -alkylsulphanyl, (C_1-C_4) -alkylsulphenyl, (C_1-C_4) -alkylsulphonyl, (C_1-C_4) -alkyloxy-SO₂-, (C_1-C_4) -alkyl-SO₂O-, -NR₂R₃, -CONR₂R₃, (C_1-C_4) -alkyl optionally substituted by one or several -OH or -F, and (C_1-C_4) -alkoxyl optionally substituted by one or several -OH or -F;
- a.d) a radical from a five- or six-membered heterocycle containing from one to three heteroatoms selected from O, S and N, this heterocycle being optionally substituted by one or several radicals independently selected from -OH, oxo (=O), -CHO, -SH, -NO₂, -CN, -F, -Cl, -Br, (C_1-C_4) -alkanoyl, (C_1-C_4) -alkoxycarbonyl, (C_1-C_4) -alkanoyloxy, (C_1-C_4) -alkylsulphanyl, (C_1-C_4) -alkylsulphenyl,

(C₁-C₄)-alkylsulphonyl,

(C₁-C₄)-alkyloxy-SO₂- , (C₁-C₄)-alkyl-SO₂O- ,

-NR₂R₃, -CONR₂R₃, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F;

a.e) phenyl or phenyl optionally substituted by one or several radicals independently selected from -OH, -CHO, -SH, -NO₂, -CN, -F, -Cl, -Br, (C₁-C₄)-alkanoyl, (C₁-C₄)-alkoxycarbonyl, (C₁-C₄)-alkanoyloxy, (C₁-C₄)-alkylsulphanyl, (C₁-C₄)-alkylsulphenyl, (C₁-C₄)-alkylsulphonyl, (C₁-C₄)-alkyloxy-SO₂- , (C₁-C₄)-alkyl-SO₂O- , -NR₂R₃, -CONR₂R₃, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F; and

a.f) a radical from a bicyclic system consisting of a benzene fused with a five- or six-membered ring optionally containing from one to three heteroatoms selected from O, S and N, being this bicyclic system optionally substituted by one or several radicals independently selected from -OH, oxo (=O), -CHO, -SH, -NO₂, -CN, -F, -Cl, -Br, (C₁-C₄)-alkanoyl, (C₁-C₄)-alkoxycarbonyl, (C₁-C₄)-alkanoyloxy, (C₁-C₄)-alkylsulphanyl, (C₁-C₄)-alkylsulphenyl, (C₁-C₄)-alkylsulphonyl, (C₁-C₄)-alkyloxy-SO₂- , (C₁-C₄)-alkyl-SO₂O- ,

-NR₂R₃, -CONR₂R₃, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F;

b) -(CH₂)_s-X-P-I-J-T wherein

s is 2 or 3;

-X- is selected from the group consisting of -O-, -S-, -SO-, -SO₂- and -NR₄-, being R₄ a radical selected from the group:

b.a) -H;

b.b) (C₁-C₁₀)-alkyl;

b.c) cycloalkyl, cycloalkyl-CO-, cycloalkyl-(C₁-C₃)-alkyl and cycloalkyl-(C₁-C₃)-alkanoyl, wherein the cycloalkyl is a five- or six-membered ring optionally substituted by one or several radicals selected from -OH, oxo (=O), -CHO, -SH, -NO₂, -CN, -F, -Cl, -Br, (C₁-C₄)-alkanoyl, (C₁-C₄)-alkoxycarbonyl, (C₁-C₄)-alkanoyloxy, (C₁-C₄)-alkylsulphinyl, (C₁-C₄)-alkylsulphenyl, (C₁-C₄)-alkylsulphonyl, (C₁-C₄)-alkyloxy-SO₂-, (C₁-C₄)-alkyl-SO₂O-, -NR₂R₃, -CONR₂R₃, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and -(C₁-C₄)-alkoxyl optionally substituted by one or several OH or F;

b.d) phenyl, phenyl-CO-, phenyl-(C₁-C₃)-alkyl and phenyl-(C₁-C₃)-alkanoyl, being this aromatic ring optionally substituted by one or several radicals selected from -OH, -CHO, -SH, -NO₂, -CN, -F, -Cl, -Br, (C₁-C₄)-alkanoyl, (C₁-C₄)-alkoxycarbonyl,

(C₁-C₄)-alkanoyloxy, (C₁-C₄)-alkylsulphiny, (C₁-C₄)-alkylsulphenyl,

(C₁-C₄)-alkylsulphonyl,

(C₁-C₄)-alkyloxy-SO₂- , (C₁-C₄)-alkyl-SO₂O- ,

-NR₂R₃, -CONR₂R₃, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F; and

b.e) a heterocycle, heterocycle-CO, heterocycle-(C₁-C₃)-alkyl and heterocycle-(C₁-C₃)-alkanoyl, wherein the heterocycle is a five- or six-membered ring containing from one to three heteroatoms selected from O, S and N, being this heterocycle optionally substituted by one or several radicals selected from -OH, oxo (=O), -CHO, -SH, -NO₂, -CN, -F, -Cl, -Br, (C₁-C₄)-alkanoyl, (C₁-C₄)-alkoxycarbonyl, (C₁-C₄)-alkanoyloxy, (C₁-C₄)-alkylsulphiny, (C₁-C₄)-alkylsulphenyl, (C₁-C₄)-alkylsulphonyl, (C₁-C₄)-alkyloxy-SO₂- , (C₁-C₄)-alkyl-SO₂O- , -NR₂R₃, -CONR₂R₃, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F;

-P- is a bond or a -(CH₂)₁₋₄- biradical;

-I- is as defined above;

-J- is as defined above; and

-T is a radical as defined above;

c) -(CH₂)_u-CO-NR₅-P-I-J-T wherein

u is 1 or 2;

-R₅ is a radical selected from the group:

c.a) -H;

c.b) (C₁-C₁₀)-alkyl;

c.c) cycloalkyl and cycloalkyl-(C₁-C₃)-alkyl, wherein the cycloalkyl is a five- or six-membered ring optionally substituted by one or several radicals selected from -OH, oxo (=O), -CHO, -SH, -NO₂, -CN, -F, -Cl, -Br, (C₁-C₄)-alkanoyl, (C₁-C₄)-alkoxycarbonyl, (C₁-C₄)-alkanoyloxy, (C₁-C₄)-alkylsulphanyl, (C₁-C₄)-alkylsulphenyl, (C₁-C₄)-alkylsulphonyl, (C₁-C₄)-alkyloxy-SO₂-, (C₁-C₄)-alkyl-SO₂O-, -NR₂R₃, -CONR₂R₃, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F;

c.d) phenyl and phenyl-(C₁-C₃)-alkyl, being this aromatic ring optionally substituted by one or several radicals selected from -OH, -CHO, -SH, -NO₂, -CN, -F, -Cl, -Br, (C₁-C₄)-alkanoyl, (C₁-C₄)-alkoxycarbonyl, (C₁-C₄)-alkanoyloxy, (C₁-C₄)-alkylsulphanyl, (C₁-C₄)-alkylsulphenyl, (C₁-C₄)-alkylsulphonyl, (C₁-C₄)-alkyloxy-SO₂-, (C₁-C₄)-alkyl-SO₂O-, -NR₂R₃, -CONR₂R₃, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F; and

c.e) a heterocycle and heterocycle-(C₁-C₃)-alkyl, wherein the heterocycle is a five- or six-membered ring

containing from one to three heteroatoms selected from O, S and N, being this heterocyclo optionally substituted by one or several radicals selected from -OH, oxo (=O), -CHO, -SH, -NO₂, -CN, -F, -Cl, -Br, (C₁-C₄)-alkanoyl, (C₁-C₄)-alkoxycarbonyl, (C₁-C₄)-alkanoyloxy, (C₁-C₄)-alkylsulphanyl, (C₁-C₄)-alkylsulphenyl, (C₁-C₄)-alkylsulphonyl, (C₁-C₄)-alkyloxy-SO₂-, (C₁-C₄)-alkyl-SO₂O-, -NR₂R₃, -CONR₂R₃, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F;

-P- is as defined above;

-I- is as defined above;

-J- is as defined above; and

-T is as defined above;

d) -(CH₂)_s-NR₆R₇, wherein s is as defined above, and R₆ and R₇ together with the N are joined forming a five- or six-membered cycle optionally containing from one to three additional heteroatoms selected from O, S and N, and that may be fused or substituted by one or two five- or six-membered cycles optionally containing one or several heteroatoms selected from the group composed of O, S and N, all the cycles being optionally substituted by one or several radicals independently selected from -OH, oxo (=O), -CHO, -SH, -NO₂, -CN, -F, -Cl, -Br, (C₁-C₄)-alkanoyl, (C₁-C₄)-alkoxycarbonyl, (C₁-C₄)-alkanoyloxy, (C₁-C₄)-alkylsulphanyl, (C₁-C₄)-alkylsulphenyl, (C₁-C₄)-alkylsulphonyl, (C₁-C₄)-alkyloxy-SO₂-,

(C₁-C₄)-alkyl-SO₂O-, -NR₂R₃, -CONR₂R₃,
(C₁-C₄)-alkyl optionally substituted by one or
several -OH or -F, and (C₁-C₄)-alkoxyl optionally
substituted by one or several -OH or -F; and
e) -(CH₂)_u-CO-NR₆R₇ wherein u is as defined above,
and R₆ and R₇ are as defined above;

with the proviso that compound of formula (I) is neither
2-(4-benzyloxybenzoylamino)-3-phenylpropionic acid, nor
2-[4-(4-methoxybenzyloxy)benzoylamino]-3-phenylpropionic
acid, nor
2-[4-(4-bromobenzyloxy)benzoylamino]-3-phenylpropionic acid.

2. The compound according to claim 1, wherein W is
-NH-CH(E)-.

3. The compound according to claim 2, wherein -Z is a radical
of the -Q-I-J-T type.

4. The compound according to claim 2, wherein -Z is a radical
of the -(CH₂)_s-X-P-I-J-T type.

5. The compound according to claim 4, wherein -X- is -O-.

6. The compound according to claim 4, wherein s is 2 and -X-
is -NR₄-.

7. The compound of claim 1, wherein W is -N(E)-CH₂-CH₂-.

8. The compound according to claim 7, wherein -Z is a radical
of the -Q-I-J-T type.

9. The compound according to claim 7, wherein -Z is a radical of the -(CH₂)_s-X-P-I-J-T type.

10. The compound according to claim 9, wherein -X- is -O-.

11. The compound according to claim 9, wherein s is 2 and -X- is -NR₄-.

12. The compound according to claim 1, wherein -A is an -OR₁ type radical.

13. The compound according to claim 1 selected from the group consisting of:

(2S)-3-(4-benzyloxyphenyl)-2-[4-(4-butoxybenzyloxy)benzoylamino]propionic acid methyl ester;

(2S)-3-(4-benzyloxyphenyl)-2-[4-(3-bromobenzyloxy)benzoylamino]propionic acid methyl ester;

(2S)-3-(4-benzyloxyphenyl)-2-[4-(2-chlorobenzyloxy)benzoylamino]propionic acid methyl ester;

(2S)-3-(4-benzyloxyphenyl)-2-[4-(2-fluorobenzyloxy)benzoylamino]propionic acid methyl ester;

(2S)-3-(4-benzyloxyphenyl)-2-[4-(3-methylbenzyloxy)benzoylamino]propionic acid methyl ester;

(2S)-3-(4-benzyloxyphenyl)-2-[4-(3-trifluoromethylbenzyloxy)benzoylamino]propionic acid methyl ester;

(2S)-3-(4-benzyloxyphenyl)-2-[4-(2-methoxybenzyloxy)benzoylamino]propionic acid methyl ester;

(2S)-3-(4-benzyloxyphenyl)-2-[4-(2-methylbenzyloxy)benzoylamino]propionic acid methyl ester;

(2S)-3-(4-benzyloxyphenyl)-2-[4-(2-trifluoromethylbenzyloxy)benzoylamino]propionic acid methyl ester;

(2*S*) -3- (4-benzyloxyphenyl) -2- [4- (2-*o*-tolylethoxy)benzoylamino]propionic acid methyl ester;

(2*S*) -3- (4-benzyloxyphenyl) -2- {4- [3- (4-propoxypheenoxy)propoxy]benzoylamino}propionic acid methyl ester;

(2*S*) -3- (4-benzyloxyphenyl) -2- [4- (3-methoxybenzyloxy)benzoylamino]propionic acid methyl ester;

(2*S*) -3- (4-benzyloxyphenyl) -2- [4- (2-ethoxybenzyloxy)benzoylamino]propionic acid methyl ester;

(2*S*) -3- (4-benzyloxyphenyl) -2- [4- (4-butylbenzyloxy)benzoylamino]propionic acid methyl ester;

(2*S*) -2- [4- (4-butylbenzyloxy)benzoylamino] -3-cyclohexylpropionic acid methyl ester;

(2*S*) -2- {4- [2- (3-methylquinoxalin-2-*y*loxy)ethoxy]benzoylamino} -3-phenylpropionic acid methyl ester;

(2*S*) -3- (4-benzyloxyphenyl) -2- [4- (2-pyridin-2-*y*lethoxy)benzoylamino]propionic acid methyl ester;

(2*S*) -3- (4-benzyloxyphenyl) -2- {4- [2- (3-methylquinoxalin-2-*y*loxy)ethoxy]benzoylamino}propionic acid methyl ester;

(2*S*) -3- (4-benzyloxyphenyl) -2- {4- [2- (pyridin-2-*y*loxy)ethoxy]benzoylamino}propionic acid methyl ester;

(2*S*) -3- (4-benzyloxyphenyl) -2- {4- [2- (quinolin-8-*y*loxy)ethoxy]benzoylamino}propionic acid methyl ester;

(2*S*) -3- (4-benzyloxyphenyl) -2- {4- [2- (quinolin-7-*y*loxy)ethoxy]benzoylamino}propionic acid methyl ester;

(2*S*) -3- (4-benzyloxyphenyl) -2- {4- [2- (quinolin-2-*y*loxy)ethoxy]benzoylamino}propionic acid methyl ester;

(2*S*) -3- (4-benzyloxyphenyl) -2- {4- [3- (3-methylquinoxalin-2-*y*loxy)propoxy]benzoylamino}propionic acid methyl ester;

(2*S*) -3- (4-bromophenyl) -2- {4- [2- (3-methylquinoxalin-2-*y*loxy)ethoxy]benzoylamino}propionic acid methyl ester;

(2*S*) -3- (4-fluorophenyl) -2- {4- [2- (3-methylquinoxalin-2-*y*loxy)ethoxy]benzoylamino}propionic acid methyl ester;

(2*S*) -3- (4-benzyloxyphenyl) -2- {4- [2- (3-methylquinoxalin-2-
yloxy)ethoxy]benzoylamino}propionic acid ethyl ester;
(2*S*) -3- (4-benzyloxyphenyl) -2- {4- [2- (3-methylquinoxalin-2-
yloxy)ethoxy]benzoylamino}propionic acid isopropyl ester;
(2*S*) -3- (4-benzyloxyphenyl) -2- {4- [2- (3-methylquinoxalin-2-
yloxy)ethoxy]benzoylamino}propionic acid propyl ester;
(2*S*) -2- (4-benzyloxybenzoylamino) -3- (4-benzyloxyphenyl)propion-
ic acid;
(2*S*) -2- [4- (3-benzyloxybenzyl)oxy]benzoylamino] -3- (4-
benzyloxyphenyl)propionic acid;
3- { (3-benzyloxybenzyl) - [4- (2-
dibenzylaminoethoxy)benzoyl]amino}propionic acid;
3- { (3-benzyloxybenzyl) - {3- [2- (3-methylquinoxalin-2-
yloxy)ethoxy]benzoyl}amino}propionic acid;
3- { (3-benzyloxybenzyl) - [4- (3-benzyloxybenzyl)oxy]benzoyl]amino
}propionic acid;
2- [4- (4-benzyloxybenzyl)oxy]benzoylamino] -3- (4-benzyloxyphenyl
)propionic acid;
(2*S*) -2- [3- (4-benzyloxybenzyl)oxy]benzoylamino] -3- (4-
benzyloxyphenyl)propionic acid;
3- (4-benzyloxyphenyl) -2- [3- (biphenyl-4-ylmethoxy)benzoylamino
]propionic acid;
2- [4- (3-benzyloxybenzyl)oxy]benzoylamino] -3- (4-bromophenyl)pro-
pionic acid;
3- (4-benzyloxyphenyl) -2- [4- (4-butylbenzyl)oxy]benzoylamino]pro-
pionic acid;
2- [4- (4-butylbenzyl)oxy]benzoylamino] -3-cyclohexylpropionic
acid;
{ (3-benzyloxybenzyl) - [4- (4-butylbenzyl)oxy]benzoyl]amino}aceti-
c acid;
3- { (3-benzyloxybenzyl) - [4- (4-butylbenzyl)oxy]benzoyl]amino}pro-
pionic acid;

3-(4-benzyloxyphenyl)-2-[4-(2-bromobenzyloxy)benzoylamino]propionic acid;

3-(4-benzyloxyphenyl)-2-[4-(2-chlorobenzyloxy)benzoylamino]propionic acid;

3-(4-benzyloxyphenyl)-2-[4-(2-methylbenzyloxy)benzoylamino]propionic acid;

3-(4-benzyloxyphenyl)-2-[4-(3-trifluoromethylbenzyloxy)benzoylamino]propionic acid; and

3-(4-benzyloxyphenyl)-2-[4-(2-trifluoromethylbenzyloxy)benzoylamino]propionic acid.

14. A pharmaceutical composition comprising, as an active ingredient, a therapeutically effective amount of the compound according to any one of the claims 1 to 13 together with appropriate amounts of pharmaceutically acceptable excipients.

15. Use of the compound as defined in any one of claims 1 to 13 for the manufacture of a medicament for the prophylactic and/or curative treatment of diseases in an animal including a human.

16. Use of the compound as defined in any one of claims 1 to 13 for the manufacture of a medicament for the prophylactic and/or curative treatment of PPAR γ mediated diseases in an animal including a human.

17. Use of the compound as defined in any one of claims 1 to 13 for the manufacture of a medicament for the prophylactic and/or curative treatment of PPAR γ / PPAR δ mediated diseases in an animal including a human..

18. Use of the compound as defined in any one of claims 1 to 13 for the manufacture of a medicament for the prophylactic and/or curative treatment of a condition associated with a metabolic disease in an animal including a human.
19. Use according to claim 18, wherein the metabolic disease is non-insulin-dependent diabetes mellitus (NIDDM).
20. Use according to claim 18, wherein the metabolic disease is obesity.
21. Use according to claim 18, wherein the metabolic disease is selected from hypercholesterolaemia, and other lipid-mediated pathologies.
22. Use of the compound as defined in any one of claims 1 to 13 for the manufacture of a medicament for the prophylactic and/or curative treatment of a cardiovascular disease associated with metabolic syndrome in an animal including a human.
23. Use of the compound as defined in any one of claims 1 to 13 for the manufacture of a medicament for the prophylactic and/or curative treatment of inflammation or an inflammatory process in general in an animal including a human.
24. Use according to claim 23, wherein the inflammatory process is selected from rheumatoid arthritis, and atherosclerosis.
25. Use according to claim 23, wherein the inflammatory process is selected from psoriasis, and intestinal inflammatory disease.

26. Use of the compound as defined in any one of claims 1 to 13 for the manufacture of a medicament for the prophylactic and/or curative treatment of a bone disease, particularly osteoporosis, in an animal including a human.
27. Use of the compound as defined in any one of claims 1 to 13 for the manufacture of a medicament for the prophylactic and/or curative treatment of cancer in an animal including a human.
28. Use of the compound as defined in any one of claims 1 to 13 for the manufacture of a medicament for the prophylactic and/or curative treatment of skin wound healing or cutaneous disorders associated with an anomalous differentiation of epidermic cells, particularly the formation of keloids, in an animal including a human.
29. Use according to any of the claims 15 to 28, wherein the medicament is administered orally, parenterally or topically.
30. A method for the prophylactic and/or curative treatment of a condition mediated by PPAR γ in an animal including a human, comprising administering a therapeutically effective amount of a compound as defined in claim 1 together with an appropriate amount of pharmaceutically acceptable excipients.
31. A method for the prophylactic and/or curative treatment of a condition mediated by both PPAR γ and PPAR δ in an animal including a human, comprising administering a therapeutically effective amount of a compound as defined in claim 1 together with an appropriate amount of pharmaceutically acceptable excipients.

32. The method according to any one of claims 30 or 31, wherein the administration is carried out orally, parenterally or topically.

33. A method for the prophylactic and/or curative treatment of an animal including a human, suffering from a condition associated with metabolic diseases, comprising administering a therapeutically effective amount of a compound as defined in claim 1 together with an appropriate amount of pharmaceutically acceptable excipients.

34. A method for the prophylactic and/or curative treatment of an animal including a human, suffering from a cardiovascular disease associated with metabolic syndrome, comprising administering a therapeutically effective amount of a compound as defined in claim 1 together with an appropriate amount of pharmaceutically acceptable excipients.

35. A method for the prophylactic and/or curative treatment of an animal, including a human, suffering from inflammation or an inflammatory process in general, comprising administering a therapeutically effective amount of a compound as defined in claim 1 together with an appropriate amount of pharmaceutically acceptable excipients.

36. A method for the prophylactic and/or curative treatment of an animal, including a human, suffering from bone diseases comprising administering a therapeutically effective amount of a compound as defined in claim 1 together with an appropriate amount of pharmaceutically acceptable excipients.

37. A method for the prophylactic and/or curative treatment of an animal, including a human, suffering from cancer, comprising administering a therapeutically effective amount of a compound as defined in claim 1 together with an appropriate amount of pharmaceutically acceptable excipients.

38. A method for the prophylactic and/or curative treatment of an animal, including a human, suffering from skin wound healing or cutaneous disorders associated with an anomalous differentiation of epidermic cells, particularly the formation of keloids, comprising administering a therapeutically effective amount of a compound as defined in claim 1 together with an appropriate amount of pharmaceutically acceptable excipients.